Sichuan Hebang Biotechnology Past Earnings Performance
Past criteria checks 2/6
Sichuan Hebang Biotechnology has been growing earnings at an average annual rate of 33.6%, while the Chemicals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 15.1% per year. Sichuan Hebang Biotechnology's return on equity is 4.7%, and it has net margins of 10.9%.
Key information
33.6%
Earnings growth rate
33.8%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 15.1% |
| Return on equity | 4.7% |
| Net Margin | 10.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Sichuan Hebang Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 8,429 | 916 | 479 | 47 |
| 31 Dec 23 | 8,824 | 1,283 | 471 | 47 |
| 30 Sep 23 | 8,980 | 1,398 | 534 | 72 |
| 30 Jun 23 | 9,651 | 1,789 | 669 | 69 |
| 31 Mar 23 | 12,347 | 3,161 | 796 | 69 |
| 31 Dec 22 | 13,039 | 3,807 | 883 | 68 |
| 30 Sep 22 | 13,353 | 4,438 | 701 | 34 |
| 30 Jun 22 | 13,517 | 4,741 | 612 | 34 |
| 31 Mar 22 | 11,409 | 3,815 | 454 | 33 |
| 31 Dec 21 | 9,987 | 3,018 | 341 | 33 |
| 30 Sep 21 | 8,494 | 2,248 | 234 | 33 |
| 30 Jun 21 | 6,768 | 908 | 203 | 36 |
| 31 Mar 21 | 5,902 | 319 | 267 | 37 |
| 31 Dec 20 | 5,261 | 41 | 310 | 40 |
| 30 Sep 20 | 5,115 | -147 | 457 | 41 |
| 30 Jun 20 | 5,351 | 264 | 520 | 40 |
| 31 Mar 20 | 5,565 | 372 | 510 | 40 |
| 31 Dec 19 | 5,969 | 517 | 498 | 38 |
| 30 Sep 19 | 6,200 | 380 | 586 | 38 |
| 30 Jun 19 | 6,154 | 387 | 563 | 34 |
| 31 Mar 19 | 6,285 | 426 | 570 | 33 |
| 31 Dec 18 | 6,009 | 363 | 548 | 31 |
| 30 Sep 18 | 5,990 | 622 | 517 | 37 |
| 30 Jun 18 | 5,625 | 535 | 453 | 50 |
| 31 Mar 18 | 4,961 | 395 | 458 | 42 |
| 31 Dec 17 | 4,738 | 518 | 459 | 35 |
| 30 Sep 17 | 4,400 | 477 | 438 | 19 |
| 30 Jun 17 | 4,041 | 451 | 436 | 0 |
| 31 Mar 17 | 3,722 | 436 | 419 | 0 |
| 31 Dec 16 | 3,463 | 318 | 396 | 0 |
| 30 Sep 16 | 3,206 | 260 | 351 | 0 |
| 30 Jun 16 | 2,954 | 226 | 328 | 0 |
| 31 Mar 16 | 3,043 | 255 | 301 | 0 |
| 31 Dec 15 | 2,863 | 240 | 246 | 0 |
| 30 Sep 15 | 2,757 | 144 | 239 | 0 |
| 30 Jun 15 | 2,628 | 135 | 206 | 0 |
| 31 Mar 15 | 2,282 | 679 | 173 | 0 |
| 31 Dec 14 | 2,186 | 672 | 179 | 0 |
| 30 Sep 14 | 1,979 | 715 | 190 | 0 |
| 30 Jun 14 | 1,871 | 696 | 166 | 0 |
| 31 Mar 14 | 1,660 | 54 | 160 | 0 |
| 31 Dec 13 | 1,603 | 64 | 150 | 0 |
| 30 Sep 13 | 1,428 | 57 | 131 | 0 |
| 30 Jun 13 | 1,341 | 108 | 130 | 0 |
Quality Earnings: 603077 has high quality earnings.
Growing Profit Margin: 603077's current net profit margins (10.9%) are lower than last year (25.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603077's earnings have grown significantly by 33.6% per year over the past 5 years.
Accelerating Growth: 603077's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603077 had negative earnings growth (-71%) over the past year, making it difficult to compare to the Chemicals industry average (-19.8%).
Return on Equity
High ROE: 603077's Return on Equity (4.7%) is considered low.